Fundación MEDINA

Inicio
España
Granada, Andalucía
Fundación MEDINA

Cómo llegar Página web

Discovery of new bioactive compounds and innovative therapies
for unmet medical needs and high-value biotechnological products

MEDINA is an independent and non profit Research Organization developing innovative programs, collaborations and contracts with academic and industrial partners worldwide. MEDINA owns one of the largest Microbial Collections and the most chemically diverse Natural Products Libraries

Our team has unique expertise in natural products microbiology, chemistry and high throughput screening, as well as in early preclinical safety, drug metabolism and bioanalysis. We are currently active in drug discovery programs in infectious diseases (including tuberculosis and parasitic diseases),cancer, neurodegeneration, and rare diseases. Leveraging our unique strengths in high resolution-high throughput analytics and bioanalytics we are collaborating with clinical investigators in translational research programs for biomarker discovery and metabolomic profiling of patient samples. We are currently active in drug and biomarker discovery programs in infectious and neglected diseases cancer, CNS, and rare diseases. MEDINA is a Research Organization established in the Health Sciences Technology Park, Granada (Spain) as a private-public partnership between the Government of Andalucía (Spain), the University of Granada and Merck Sharp and Dohme de España S.A.

23/10/2026

🌱 Bringing microbial biodiversity into the conversation on sustainable crop protection.

Victor Gonzalez Menendez , Principal Scientist in Microbiology and Fungal Collection Manager at Fundación MEDINA, presented our poster at ABIM 2026, showcasing MEDINA’s integrated discovery platform for identifying new microbial natural products with activity against plant pathogens.

A great opportunity to exchange ideas with the biocontrol community and explore how microbial diversity can contribute to the next generation of biopesticides.
ABIM - Annual Biocontrol Industry Meeting

21/10/2026

One of the biggest challenges in natural products research is distinguishing truly novel chemistry from compounds that have already been described.

Without early characterisation, time and resources can be invested in isolating and characterising molecules that are already known.

At Fundación MEDINA, we assess novelty at an early stage and focus attention on the most promising chemistry.

Do you want to know more about our pipeline? Swipe through and contact us to discuss how we can support your next project.

19/10/2026

On , we are excited to share our recently published study in Scientific Reports!
🔬 “Label-free morphometric profiling reveals early drug responses in 3D tumor spheroids”

In this work, we introduce m3DinAI Drug Quest, a high-content imaging platform that combines 3D tumor spheroids with label-free, longitudinal morphological profiling to characterize drug responses in triple-negative breast cancer (TNBC).

💡 What makes our approach different?
Rather than relying exclusively on conventional cell viability assays, we analyze how tumor spheroids change their morphology over time in response to treatment.
Our study demonstrates that:
🔹 Label-free imaging can reveal early drug-induced morphological changes that conventional viability assays may miss.
🔹 The Morphological Disruption Concentration (MDC) provides a complementary metric for quantifying drug responses.
🔹 Multiparametric morphological profiling can distinguish treatment-specific phenotypes and different drug classes.

By combining physiologically relevant 3D cancer models with scalable phenotypic profiling, we aim to contribute to more informative preclinical drug discovery.

👏 this work was led by Dr. Rosario Fernández - Godino. Congratulations to Inmaculada Iáñez García, Dr. Marta Martínez García, and Dr. Carmen Ramos Martin for their contributions to this work!
📖 Read our open-access publication:
https://www.nature.com/articles/s41598-026-74860-2 -information
Fundación MEDINA

15/10/2026

🌱 From microbial biodiversity to innovative solutions for sustainable crop protection.

We are proud to present our latest work at ABIM 2026, showcasing MEDINA's integrated discovery platform for identifying new microbial natural products with activity against plant pathogens.

Looking forward to engaging discussions on the future of biopesticides and microbial innovation in agriculture.
ABIM - Annual Biocontrol Industry Meeting Fundación MEDINA

14/10/2026

Joining forces at the XVIII SDDN Meeting in Pamplona!

From 21-23 October, Fundación MEDINA will be at the XVIII Spanish Drug Discovery Network meeting, which bring together drug discovery professionals from academia and industry.

The program features a mix of science, mentoring, and networking opportunities for all, and we are taking part in all three!

Carmen Ramos Martin, and Marta Martínez García, Scientists at Fundación MEDINA, bring two projects: SMART-TNT, on new therapies for triple-negative breast cancer, and PROSPLIGN, on bioactive molecules from lignin for the pharmaceutical, cosmetics, and fragrance industries.

Rosario Fernández-Godino, Head of Screening and Target Validation Unit and and SDDN board member, will chair the session “Accelerate your future: Fast-track mentoring for early-career scientists” a unique opportunity to boost your career with insights from experts in drug discovery from different fields.

If you are in Pamplona, come and find us!

13/10/2026

Fundación MEDINA is at Festival of Biologics 2026!

Francisco Castillo, Senior Scientist in the Screening and Target Validation Department at Fundación MEDINA, is in Basel from October 13 to 15, connecting with the biologics community and exploring new opportunities for collaboration.

Meet Francisco to discuss MEDINA's expertise in:

• Target-agnostic and target-based HTS applications
• Ternary complexes
• Quantification of biologics in complex matrices
• Discovery of naturally occurring extremophilic enzymes

Interested in connecting? 🤝 Book a meeting with Francisco through the Terrapinn Events App or send him a direct message on his personal LinkedIn profile ( Castillo).

08/10/2026

Fundación MEDINA is heading to London for Drug Discovery 2026!

On 14 and 15 October, Carmen Ramos Martin, Principal Scientist at Fundación MEDINA, will be at ELRIG Drug Discovery 2026 presenting our drug discovery work in triple negative breast cancer.
The project combines 3D tumor models, MEDINA's proprietary collection of microbial natural product extracts and our machine learning pipeline to support the discovery of new candidates against triple-negative breast cancer.
If you are attending, find Carmen at poster 276 on 14 and 15 October.

08/10/2026

Yesterday, Victor Gonzalez Menendez, PhD, Principal Scientist in Microbiology and Fungal Collection Manager at Fundación MEDINA, participated in the BIOTECH ATTRACTION Congress: New Horizons in Plant Innovation, held alongside Fruit Attraction 2026 in Madrid.

During the session “Scientific and Technological Capabilities of Excellence in Plant Biotechnology”, Víctor shared MEDINA’s expertise in microbial resources and natural products, highlighting the potential of microbial biodiversity for developing innovative and sustainable solutions in agriculture.

An excellent opportunity to showcase how MEDINA’s capabilities in microbial fermentation, biocontrol and biostimulants can contribute to innovation in the agri-food sector.

07/10/2026

Fundación MEDINA is at BioJapan 2026!

We are delighted to be in this week, connecting with the Japanese and international life sciences community and presenting Fundacion MEDINA’s capabilities in drug discovery.

Today, our Head of Screening and Target Validation, Dr. ROSARIO FERNANDEZ GODINO, presented MEDINA’s approach to advancing drug discovery through high-throughput and high-content screening, Cell Painting, advanced human cellular models, and natural product-based drug discovery.

BioJapan is a great opportunity to explore new collaborations and discuss how our technologies and expertise can support the discovery and characterization of new therapeutic candidates.

📍 BioJapan 2026 | Pacifico Yokohama
📅 October 7–9

If you are attending BioJapan and would like to learn more about MEDINA or explore potential collaborations, come and meet us at the Spain Pavilion ICEX.

07/10/2026

Our Scientific Director Olga Genilloud, is attending this week the XVIII International Symposium on Marine Natural Products in Riviera Maya, Mexico. As contribution to the conference she has presented new results on the research program developed at Fundación MEDINA on the discovery of novel bioactive natural products from marine-associated fungi.

Alongside the conference, Olga Genilloud has co-organized with Bahne Stechmann EU Openscreen Deputy Director, the EUREMAP Scientific Networking Symposium on International Collaboration Opportunities, bringing together an international group of researchers from Mexico, Brazil, USA, South Korea and EUREMAP European partners, with a clear interest in establishing new partnerships and enlarging their collaborations opportunities in the field of marine natural products research.

During , she has presented a poster showcasing one of the Demonstrator projects as case study of the production and therapeutic potential of streptocyclinones for Alzheimer’s disease and developed by from Sorbonne Univerite-CNRS, EMBL-EBI and Fundación MEDINA to validate the bioprospecting platform.

EU Openscreen Facultad de Química UNAM UNAM Universidad Nacional Autónoma de México European Research Executive Agency (REA)

Dirección

Parque Tecnológico De La Salud/Avenida Del Conocimiento, 34
Granada
18016

Página web

http://www.medinadiscovery.com/

Notificaciones

Sea el primero en enterarse: le enviaremos un correo electrónico cuando Fundación MEDINA publique novedades y promociones. Su dirección de correo electrónico no se utilizará para ningún otro fin y puede darse de baja en cualquier momento.